When it comes to approving new medical treatments, the Food and Drug Administration is balancing the need for patient safety against the urgency of making important new treatments available as quickly as possible. A team of experts recently faced off for an Intelligence Squared U.S. debate on the motion “The FDA's Caution Is Hazardous to Our Health.” Jerry Avorn, HMS professor of medicine at Brigham and Women’s Hospital, was one of the participants.
News & Research
